TABLE 3.
Estimated fold changes to secretome from co-cultures of stroke patient derived Mo and MSCs after exposure to combination of atorvastatin and Aspirin with respect to a vehicle control of atorvastatin 0 + Aspirin 0 nM. Combination of atorvastatin and Aspirin decreases the IL-6 secretion from stroke Mo-MSCs co-cultures after 24 h of exposure. In addition, there is also a decrease in MCP-1 secretions at the highest dose of atorvastatin and aspirin after 24 h of exposure. Significance is shown by p-value<0.05. FC = Fold Change, 95% CI = 95% Confidence Intervals with lower and upper limits.
| Co-cultures of stroke patient derived Mo-MSCs exposed to various dose combinations of atorvastatin and aspirin | ||||
|---|---|---|---|---|
| IL-1β | IL-6 | |||
| FC (95% CI) | p-value | FC (95% CI) | p-value | |
| Atorvastatin 800 nM + Aspirin † | 0.86 (0.30, 2.50) | 0.78 | 0.33 (0.09, 1.15) | 0.08 |
| Atorvastatin 8000 nM + Aspirin † | 0.79 (0.27, 2.30) | 0.66 | 0.26 (0.07, 0.92) | <0.05 |
| Atorvastatin 80000 nM + Aspirin † | 0.81 (0.28, 2.36) | 0.69 | 0.28 (0.08, 0.99) | <0.05 |
| Aspirin 500 nM + atorvastatin § | 0.78 (0.27, 2.27) | 0.64 | 0.31 (0.09, 1.10) | 0.07 |
| Aspirin 5000 nM + atorvastatin § | 0.98 (0.34, 2.86) | 0.98 | 0.35 (0.10, 1.23) | 0.10 |
| Aspirin 50000 nM + atorvastatin § | 0.45 (0.16, 1.31) | 0.14 | 0.17 (0.05, 0.60) | <0.05 |
| IL-8 | IL-1RA | |||
|---|---|---|---|---|
| FC (95% CI) | p -value | FC (95% CI) | p -value | |
| Atorvastatin 800 nM + aspirin † | 1.07 (0.48, 2.38) | 0.86 | 1.33 (0.88, 2.00) | 0.17 |
| Atorvastatin 8000 nM + aspirin † | 0.69 (0.31, 1.52) | 0.34 | 1.33 (0.88, 2.00) | 0.17 |
| Atorvastatin 80000 nM + aspirin † | 0.61 (0.28, 1.36) | 0.22 | 1.44 (0.95, 2.17) | 0.08 |
| Aspirin 500 nM + atorvastatin § | 0.83 (0.38, 1.85) | 0.64 | 1.41 (0.94, 2.13) | 0.10 |
| Aspirin 5000 nM + atorvastatin § | 1.04 (0.47, 2.30) | 0.93 | 1.50 (0.99, 2.26) | 0.05 |
| Aspirin 50000 nM + atorvastatin b | 0.66 (0.30, 1.47) | 0.30 | 1.32 (0.87, 1.99) | 0.18 |
| MCP-1 | TNF-α | |||
|---|---|---|---|---|
| FC (95% CI) | p -value | FC (95% CI) | p -value | |
| Atorvastatin 800 nM + aspirin † | 0.98 (0.43, 2.22) | 0.95 | 1.13 (0.57, 2.24) | 0.72 |
| Atorvastatin 8000 nM + aspirin † | 0.55 (0.24, 1.24) | 0.14 | 0.94 (0.47, 1.86) | 0.85 |
| Atorvastatin 80000 nM + aspirin † | 0.18 (0.08, 0.42) | <0.05 | 0.72 (0.36, 1.42) | 0.33 |
| Aspirin 500 nM + atorvastatin § | 0.55 (0.24, 1.25) | 0.15 | 1.06 (0.53, 2.10) | 0.87 |
| Aspirin 5000 nM + atorvastatin § | 0.71 (0.31, 1.63) | 0.41 | 0.97 (0.49, 1.93) | 0.94 |
| Aspirin 50000 nM + atorvastatin § | 0.49 (0.22, 1.12) | 0.09 | 0.70 (0.35, 1.39) | 0.30 |
Averaged over all aspirin concentrations (0, 500, 5000 and 50000 nM).
Averaged over all atorvastatin concentrations (0, 800, 8000, 80000 nM). The averaged effect over all aspirin or atorvastatin concentrations statistically reflects the uniform effect of these drugs in presence of variable doses of the other drug.